부산대학교 도서관

Background: The TAXUS OLYMPIA registry is a prospective, postapproval registry collecting clinical outcomes data on patients receiving the TAXUS Liberté paclitaxel-eluting stent during routine interventional cardiology practice. Methods: Between February and July 2005, 529 patients receiving the TAXUS Liberté stent at 16 centers in the Middle East, South/Central America, and Asia/Pacific regions were enrolled in Phase I of OLYMPIA. The primary end-point was TAXUS Liberté stent-related cardiac events (cardiac death, MI, and revascularization) at 30 days postimplant. Additional clinical assessment was conducted at 6 and 12 months. OLYMPIA phases II and III are in clinical follow-up and will be reported separately. Results: One-year clinical follow-up is available for 98% of patients. Complex patients and lesions were prevalent, including: 50% diabetes mellitus, 49% multivessel disease, 30% multiple stenting, 48% AHA/ACC type B2/C lesions, 19% long lesions (>26 mm), and 40% small vessels (≤2.75 mm). At 1 year, the cardiac event rate was 4.1%, including 1.5% cardiac death, 1.5% MI, and 2.3% target vessel revascularization (TVR). The TAXUS Liberté stent-related cardiac event rate was 3.7% at 1 year. Stent thrombosis (ST) occurred in 1.7% of patients, with three cases occurring >30 days postprocedure. One-year cardiac event rates among complex subpopulations (diabetics 5.0%, multiple stents 3.8%, long lesions 3.1%, and small vessels 2.9%) were comparable to the overall study population. Conclusions: In conclusion, this first report of real-world experience with the TAXUS Liberté stent demonstrates the safety and clinical utility of this stent in the broader spectrum of coronary disease treated in everyday practice. [ABSTRACT FROM AUTHOR]